Previous 10 | Next 10 |
- Enrollment closed with at least 76 subjects; study protocol modified in light of ongoing COVID-19 pandemic - - Revance now expects to report topline results from JUNIPER trial in early 2021 - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovativ...
Revance Therapeutics (NASDAQ: RVNC ) announces positive results from two open-label dose-escalating Phase 2a clinical trials evaluating DaxibotulinumtoxinA (DAXI) for the treatment of dynamic forehead lines following glabellar (frown) line injections and lateral canthal lines (crow...
- At least one dose in each study demonstrated a measurable treatment effect in 100% of subjects at 4 weeks, with median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet - - DaxibotulinumtoxinA for Injection was well tolerated across all doses in both indicatio...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will participate in the 40th Annual William B...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will present at the Goldman Sachs 41 st Annu...
- First neurotoxin formulation to be developed as a potential biosimilar product to BOTOX ® , potentially giving Mylan access to 14 indications upon approval - - $30 million milestone payable to Revance from Mylan - Revance Therapeutics, Inc. (NASDAQ: RVNC) and Mylan N.V. (NASDAQ...
Allergan ( ABBV -1.0% ) competitor Evolus ( EOLS +30.5% ), maker of Botox (onabotulinumtoxinA) rival Jeuveau (prabotulinumtoxinA-xvfs), jumps on a 10x surge in volume burning short sellers along the way. More news on: AbbVie Inc., Evolus, Inc., Revance Therapeutics, Inc....
Revance Therapeutics (NASDAQ: RVNC ) has agreed to acquire privately held Hint, Inc., doing business as HintMD , the developer of an integrated financial platform for the aesthetics industry, for 8.54M shares of RVNC common stock (~$180M based on yesterday's close of $21.08). More news ...
- Provides access to a $500+ million market opportunity in U.S aesthetic practice payment services - - Leverages planned commercial infrastructure across both premium facial injectables products and services platform - - Unique, differentiated and integrated digital services pla...
Privately held Galderma announces the results from a 120-subject study, DREAM, assessing the safety and patient satisfaction of Dysport (abobotulinumtoxinA) for the temporary treatment of moderate-to-severe glabellar lines (frown lines) between the eyebrows in adults less than 65 years old...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...